Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

90.29 -0.20 (-0.22%)
Streaming Delayed Price Updated: 11:25 AM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
52 53 Next >
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
-Clinical Data Due Next Week at ASH- 
Via Benzinga
Is Gilead Sciences Stock Still a Buy After Soaring in 2022?
Gilead faces some challenges. But there are several reasons to think the stock could keep the momentum going. 
Via The Motley Fool
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
From Gilead Sciences, Inc.
Via Business Wire
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Expert Ratings for Gilead Sciences
Via Benzinga
2 Reasons This Stock Could Outperform in 2023
It would be a continuation of this year's showing. 
Via The Motley Fool
Gilead Sciences Unusual Options Activity
Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
The Top Healthcare Stocks to Buy With $100
Triple-digit growth and innovation go hand-in-hand with these companies. 
Via The Motley Fool
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $17,000 Today
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
These 3 Stocks Are Rallying While the Rest of the Market Plunges
Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds. 
Via The Motley Fool
European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations
From Gilead Sciences, Inc.
Via Business Wire
Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead
Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets. 
Via Talk Markets
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges
Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher. 
Via Investor's Business Daily
Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures
Via Benzinga
What Does Gilead Sciences' Debt Look Like?
Over the past three months, shares of Gilead Sciences Inc. (NASDAQ:GILD) rose by 34.80%. Before having a look at the importance of debt, let's look at how much debt Gilead Sciences has. 
Via Benzinga
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer
From Arcus Biosciences
Via Business Wire
Pick These 4 Stocks With Exciting Interest Coverage Ratio
Let's take a look at some of the companies that boast an impressive interest coverage ratio. 
Via Talk Markets
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching. 
Via Investor's Business Daily
This Is What Whales Are Betting On Gilead Sciences
Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
2 Reasons to Buy AbbVie Stock and 1 Reason to Sell
The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem. 
Via The Motley Fool
Gilead Sciences' Debt Overview
Shares of Gilead Sciences' Inc. (NASDAQ:GILD) rose by 33.62% in the past three months. Before we understand the importance of debt, let's look at how much debt Gilead Sciences' has. 
Via Benzinga
Jim Simons 'The Man Who Solved The Market' Sold 3 Healthcare Dividend Payers, But Upped Stake In This One By 153%
Jim Simons is the founder and hedge fund manager of Renaissance Technologies, which currently has a total portfolio value north of $77 billion, per Stock Circle. This hedge fund uses a quantitative... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 50 stocks hit new 52-week highs. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
FTX Contagion Spreads To Hong Kong Exchange, Microsoft Outlines New Harassment Policies, Netflix Subscribers Can Terminate Freeloading Account Access: Top Stories Wednesday, Nov. 16
Benzinga 
Via Benzinga
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
52 53 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.